{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:07:34Z","timestamp":1788314854546,"version":"build-2803163510"},"reference-count":199,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013041","name":"Shiraz University of Medical Sciences Vice Chancellor of Research","doi-asserted-by":"publisher","award":["26784"],"award-info":[{"award-number":["26784"]}],"id":[{"id":"10.13039\/501100013041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.biopha.2023.115292","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T23:47:04Z","timestamp":1691797624000},"page":"115292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Glucarpidase (carboxypeptidase G2): Biotechnological production, clinical application as a methotrexate antidote, and placement in targeted cancer therapy"],"prefix":"10.1016","volume":"166","author":[{"given":"Fatemeh","family":"Moradbeygi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younes","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Reza","family":"Farmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9071-9569","authenticated-orcid":false,"given":"Shiva","family":"Hemmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2023.115292_bib1","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/bab.1617","article-title":"Progress in biopharmaceutical development","volume":"65","author":"Kesik\u2010Brodacka","year":"2018","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.biopha.2023.115292_bib2","doi-asserted-by":"crossref","unstructured":"M.-K. Yeh, Y.-C. Chen , Biopharmaceuticals, BoD\u2013Books on Demand (2018).","DOI":"10.5772\/intechopen.72960"},{"key":"10.1016\/j.biopha.2023.115292_bib3","article-title":"Regenerative medicine with platelet rich plasma and other blood derived products for dermatology, genitourinary disorders, musculoskeletal disorders and surgical procedures","author":"Beilin","year":"2023","journal-title":"Handb. Anti-Aging Med."},{"issue":"2","key":"10.1016\/j.biopha.2023.115292_bib4","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/1541-4337.13097","article-title":"Critical features of an in vitro intestinal absorption model to study the first key aspects underlying food allergen sensitization","volume":"22","author":"Dijk","year":"2023","journal-title":"Compr. Rev. Food Sci. Food Saf."},{"issue":"12","key":"10.1016\/j.biopha.2023.115292_bib5","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3390\/md20120763","article-title":"Polypharmacological cell-penetrating peptides from venomous marine animals based on immunomodulating, antimicrobial, and anticancer properties","volume":"20","author":"Hemmati","year":"2022","journal-title":"Mar. Drugs"},{"issue":"3","key":"10.1016\/j.biopha.2023.115292_bib6","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41591-023-02229-3","article-title":"Real-world effectiveness of a single dose of mpox vaccine in males","volume":"29","author":"Wolff Sagy","year":"2023","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.biopha.2023.115292_bib7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41577-022-00784-3","article-title":"Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses","volume":"23","author":"Chen","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2023.115292_bib8","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41434-021-00309-y","article-title":"Equitable access to cell and gene therapies in South Africa: opportunities and hurdles","volume":"30","author":"Hendricks","year":"2023","journal-title":"Gene Ther."},{"issue":"3","key":"10.1016\/j.biopha.2023.115292_bib9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2174\/1570164614666170306164830","article-title":"In silico investigation of pullulanase enzymes from various Bacillus species","volume":"14","author":"Rahmatabadi","year":"2017","journal-title":"Curr. Proteom."},{"issue":"17","key":"10.1016\/j.biopha.2023.115292_bib10","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1080\/01496395.2021.1962910","article-title":"Whole cell immobilization of recombinant E. coli cells by calcium alginate beads; evaluation of plasmid stability and production of extracellular L-asparaginase","volume":"57","author":"Ghoshoon","year":"2022","journal-title":"Sep. Sci. Technol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115292_bib11","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3390\/jcm9030736","article-title":"Glucocerebrosidase: functions in and beyond the lysosome","volume":"9","author":"Boer","year":"2020","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.biopha.2023.115292_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11696-022-02507-3","article-title":"\u03b2-galactosidase as an industrial enzyme: production and potential","volume":"77","author":"Singh","year":"2023","journal-title":"Chem. Pap."},{"key":"10.1016\/j.biopha.2023.115292_bib13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.enzmictec.2018.12.006","article-title":"Identification and characterization of a sterically robust phenylalanine ammonia-lyase among 481 natural isoforms through association of in silico and in vitro studies","volume":"122","author":"Rahmatabadi","year":"2019","journal-title":"Enzym. Microb. Technol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115292_bib14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/1389201016666150907113055","article-title":"Engineering human urate oxidase: towards reactivating it as an important therapeutic enzyme","volume":"17","author":"Dabbagh","year":"2016","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"23","key":"10.1016\/j.biopha.2023.115292_bib15","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.3390\/molecules24234318","article-title":"Considerations on the rational design of covalently conjugated cell-penetrating peptides (CPPs) for intracellular delivery of proteins: a guide to CPP selection using glucarpidase as the model cargo molecule","volume":"24","author":"Behzadipour","year":"2019","journal-title":"Molecules"},{"issue":"18","key":"10.1016\/j.biopha.2023.115292_bib16","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/cbic.201800186","article-title":"Characterisation of the Carboxypeptidase G2 catalytic site and design of new inhibitors for cancer therapy","volume":"19","author":"Jeyaharan","year":"2018","journal-title":"ChemBioChem"},{"issue":"3","key":"10.1016\/j.biopha.2023.115292_bib17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0969-2126(97)00191-3","article-title":"Crystal structure of carboxypeptidase G2, a bacterial enzyme with applications in cancer therapy","volume":"5","author":"Rowsell","year":"1997","journal-title":"Structure"},{"issue":"1","key":"10.1016\/j.biopha.2023.115292_bib18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1634\/theoncologist.2017-0243","article-title":"Consensus guideline for use of glucarpidase in patients with high\u2010dose methotrexate induced acute kidney injury and delayed methotrexate clearance","volume":"23","author":"Ramsey","year":"2018","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.biopha.2023.115292_bib19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrrheum.2010.5","article-title":"Methotrexate-how does it really work","volume":"6","author":"Chan","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"issue":"6","key":"10.1016\/j.biopha.2023.115292_bib20","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3390\/jcm10061182","article-title":"Pathogenesis and current treatment of osteosarcoma: perspectives for future therapies","volume":"10","author":"Rathore","year":"2021","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.biopha.2023.115292_bib21","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00280-020-04058-4","article-title":"Pharmacokinetics and pharmacogenetics of high-dose methotrexate in Chinese adult patients with non-Hodgkin lymphoma: a population analysis","volume":"85","author":"Yang","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115292_bib22","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/pbc.25305","article-title":"Statistical analysis of relation between plasma methotrexate concentration and toxicity in high\u2010dose methotrexate therapy of childhood nonHodgkin lymphoma","volume":"62","author":"Tsurusawa","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2023.115292_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000514135","article-title":"New therapeutic approach to reduce methotrexate toxicity after high-dose chemotherapy in a child with acute lymphocytic leukemia: efficacy and safety of hemoadsorption with HA-230 adsorber","volume":"51","author":"Sazonov","year":"2022","journal-title":"Blood Purif."},{"issue":"4","key":"10.1016\/j.biopha.2023.115292_bib24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ijpam.2016.08.008","article-title":"The frequency of hepatotoxicity and myelotoxicity in leukemic children with different high doses of methotrexate","volume":"3","author":"\u00d6zdemir","year":"2016","journal-title":"Int. J. Pediatr. Adolesc. Med."},{"issue":"9","key":"10.1016\/j.biopha.2023.115292_bib25","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2217\/pgs-2019-0062","article-title":"Genetics of high-dose methotrexate-induced oral mucositis: current perspectives","volume":"20","author":"Heil","year":"2019","journal-title":"Pharmacogenomics"},{"issue":"4","key":"10.1016\/j.biopha.2023.115292_bib26","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1177\/1078155220953878","article-title":"Significant interaction between high-dose methotrexate and high-dose piperacillin-tazobactam causing reversible neurotoxicity and renal failure in an osteosarcoma patient","volume":"27","author":"Kr\u00e4mer","year":"2021","journal-title":"J. Oncol. Pharm. Pract. Off. Publ. Int. Soc. Oncol. Pharm. Pract."},{"issue":"4","key":"10.1016\/j.biopha.2023.115292_bib27","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1080\/10428194.2020.1846733","article-title":"Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patients","volume":"62","author":"Medrano","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"9\u201310","key":"10.1016\/j.biopha.2023.115292_bib28","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10930-009-9211-2","article-title":"Functional overexpression and purification of a codon optimized synthetic glucarpidase (carboxypeptidase G2) in Escherichia coli","volume":"28","author":"Goda","year":"2009","journal-title":"Protein J."},{"key":"10.1016\/j.biopha.2023.115292_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110009","article-title":"Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine","volume":"125","author":"Bashraheel","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.biopha.2023.115292_bib30","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich's magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat. Rev. Cancer"},{"issue":"22","key":"10.1016\/j.biopha.2023.115292_bib31","doi-asserted-by":"crossref","first-page":"6903","DOI":"10.1016\/j.bmcl.2012.09.029","article-title":"Development of triazene prodrugs for ADEPT strategy: new insights into drug delivery system based on carboxypeptidase G2 activation","volume":"22","author":"Capucha","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"11","key":"10.1016\/j.biopha.2023.115292_bib32","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/nrc2247","article-title":"Carboxypeptidase G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury","volume":"7","author":"Hedley","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2023.115292_bib33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40495-016-0073-y","article-title":"Enzyme\/prodrug systems for cancer gene therapy","volume":"2","author":"Malekshah","year":"2016","journal-title":"Curr. Pharmacol. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2023.115292_bib34","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.annemergmed.2017.05.021","article-title":"Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care","volume":"71","author":"Dart","year":"2018","journal-title":"Ann. Emerg. Med."},{"issue":"3","key":"10.1016\/j.biopha.2023.115292_bib35","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s13181-023-00943-5","article-title":"Pharmaceutical Purchasing: a Review of the Landscape and Implications for antidotal therapies","volume":"19","author":"Troger","year":"2023","journal-title":"J. Med. Toxicol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115292_bib36","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1128\/jb.156.3.1222-1227.1983","article-title":"Molecular cloning of the Pseudomonas carboxypeptidase G2 gene and its expression in Escherichia coli and Pseudomonas putida","volume":"156","author":"Minton","year":"1983","journal-title":"J. Bacteriol."},{"issue":"4","key":"10.1016\/j.biopha.2023.115292_bib37","first-page":"897","article-title":"Expression of the Pseudomonas gene coding for carboxypeptidase G2 in Saccharomyces cerevisiae","volume":"131","author":"Clarke","year":"1985","journal-title":"J. Gen. Microbiol."},{"issue":"6","key":"10.1016\/j.biopha.2023.115292_bib38","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/BF00260987","article-title":"Plasmid pMTL153: a high copy number version of pAT153 and its use to obtain high expression of the Pseudomonas carboxypeptidase G2 gene","volume":"29","author":"Chambers","year":"1988","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"10","key":"10.1016\/j.biopha.2023.115292_bib39","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/BF01044100","article-title":"Production of cloned carboxypeptidase G2 by Escherichia coli: genetic and environmental considerations","volume":"11","author":"Lancaster","year":"1989","journal-title":"Biotechnol. Lett."},{"issue":"10","key":"10.1016\/j.biopha.2023.115292_bib40","first-page":"8","article-title":"Cloning, expression and Characterization of Carboxypeptidase G2 Enzyme from E. coli","volume":"26","author":"Aalizade","year":"2019","journal-title":"Razi J. Med. Sci."},{"key":"10.1016\/j.biopha.2023.115292_bib41","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.pep.2016.06.015","article-title":"Soluble expression, purification and functional characterisation of carboxypeptidase G2 and its individual domains","volume":"127","author":"Jeyaharan","year":"2016","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.biopha.2023.115292_bib42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejps.2018.10.014","article-title":"Production of \u201cbiobetter\u201d glucarpidase variants to improve drug detoxification and antibody directed enzyme prodrug therapy for cancer treatment","volume":"127","author":"AlQahtani","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2023.115292_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108725","article-title":"Production of \u201cbiobetter\u201d variants of glucarpidase with enhanced enzyme activity","volume":"112","author":"Al-Qahtani","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2023.115292_bib44","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0006-2952(87)90387-X","article-title":"Covalent linkage of carboxypeptidase G2 to soluble dextrans-I properties of conjugates and effects on plasma persistence in mice","volume":"36","author":"Melton","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115292_bib45","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211057371","article-title":"Production of long-acting CNGRC-CPG2 fusion proteins: new derivatives to overcome drug immunogenicity of ligand-directed enzyme prodrug therapy for targeted cancer treatment","volume":"20","author":"Al-Mansoori","year":"2021","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.biopha.2023.115292_bib46","doi-asserted-by":"crossref","unstructured":"L.J. Al-Mansoori, P. Elsinga, S. Goda, Production of active long lasting CNGRC-CPG2 fusion protein using PEGylation to be used in Ligand Directed Cancer Therapy, (2020).","DOI":"10.29117\/quarfe.2020.0185"},{"issue":"6","key":"10.1016\/j.biopha.2023.115292_bib47","doi-asserted-by":"crossref","first-page":"619","DOI":"10.18632\/oncotarget.27478","article-title":"In vitro studies on CNGRC-CPG2 fusion proteins for ligand-directed enzyme prodrug therapy for targeted cancer therapy","volume":"11","author":"Al-Mansoori","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2023.115292_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2020.104474","article-title":"Decoding the proteome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for cell-penetrating peptides involved in pathogenesis or applicable as drug delivery vectors","volume":"85","author":"Hemmati","year":"2020","journal-title":"Infect. Genet. Evol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115292_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/btpr.3071","article-title":"Introducing a delivery system for melanogenesis inhibition in melanoma B16F10 cells mediated by the conjugation of tyrosine ammonia\u2010lyase and a TAT\u2010penetrating peptide","volume":"37","author":"Behzadipour","year":"2021","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.biopha.2023.115292_bib50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.taap.2018.03.023","article-title":"TAT-mediated intracellular delivery of carboxypeptidase G2 protects against methotrexate-induced cell death in HepG2 cells","volume":"346","author":"Sadeghian","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"42","key":"10.1016\/j.biopha.2023.115292_bib51","first-page":"95","article-title":"Heterologous expression, purification and determination of activity of new carboxypepetidase from cohnella Ao1","volume":"11","author":"Naeemi","year":"2021","journal-title":"New Cell. Mol. Biotechnol. J."},{"key":"10.1016\/j.biopha.2023.115292_bib52","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.biochi.2022.12.003","article-title":"In vitro and in silico characterization of a novel glutamate carboxypeptidase from Cohnella sp. A01","volume":"207","author":"Naeemi","year":"2023","journal-title":"Biochimie"},{"issue":"12","key":"10.1016\/j.biopha.2023.115292_bib53","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s12033-021-00370-3","article-title":"Characterization of a Stable Form of Carboxypeptidase G2 (Glucarpidase), a potential biobetter variant, from acinetobacter sp. 263903-1","volume":"63","author":"Sadeghian","year":"2021","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.biopha.2023.115292_bib54","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.enzmictec.2016.01.005","article-title":"The 46kDa dimeric protein from Variovorax paradoxus shows faster methotrexate degrading activity in its nanoform compare to the native enzyme","volume":"85","author":"Bayineni","year":"2016","journal-title":"Enzym. Microb. Technol."},{"key":"10.1016\/j.biopha.2023.115292_bib55","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.procbio.2019.09.030","article-title":"Biochemical insights into a novel thermo\/organo tolerant bilirubin oxidase from Thermosediminibacter oceani and its application in dye decolorization","volume":"88","author":"Sadeghian","year":"2020","journal-title":"Process Biochem."},{"key":"10.1016\/j.biopha.2023.115292_bib56","doi-asserted-by":"crossref","unstructured":"D.S. Hage, J.A. Anguizola, R. Li, R. Matsuda, E. Papastavros, E. Pfaunmiller, M. Sobansky, X. Zheng, Affinity chromatography, Liquid chromatography, Elsevier2023, pp. 539\u2013561.","DOI":"10.1016\/B978-0-323-99968-7.00034-5"},{"issue":"1","key":"10.1016\/j.biopha.2023.115292_bib57","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0167-4838(82)90296-5","article-title":"Metal ion-promoted binding of proteins to immobilized triazine dye affinity adsorbents","volume":"700","author":"Hughes","year":"1982","journal-title":"Biochim. Et. Biophys. Acta (BBA)\/Protein Struct. Mol."},{"issue":"C","key":"10.1016\/j.biopha.2023.115292_bib58","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0021-9673(00)82346-8","article-title":"High-performance liquid affinity chromatography of enzymes on silica-immobilised triazine dyes","volume":"216","author":"Small","year":"1981","journal-title":"J. Chromatogr. A"},{"issue":"3","key":"10.1016\/j.biopha.2023.115292_bib59","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1432-1033.1985.tb08860.x","article-title":"Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method","volume":"148","author":"Sherwood","year":"1985","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.biopha.2023.115292_bib60","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijbiomac.2016.12.042","article-title":"Chitosan and carboxymethyl cellulose based magnetic nanocomposites for application of peroxidase purification","volume":"96","author":"Zengin Kurt","year":"2017","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.biopha.2023.115292_bib61","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pep.2016.09.001","article-title":"Going native: complete removal of protein purification affinity tags by simple modification of existing tags and proteases","volume":"129","author":"Goh","year":"2017","journal-title":"Protein Expr. Purif."},{"issue":"1","key":"10.1016\/j.biopha.2023.115292_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2022.102036","article-title":"Purification of hetero-oligomeric protein variants using a modified tandem affinity purification approach","volume":"4","author":"Parui","year":"2023","journal-title":"STAR Protoc."},{"key":"10.1016\/j.biopha.2023.115292_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.pep.2022.106186","article-title":"One-step metal affinity purification of recombinant hFGF19 without using tags","volume":"201","author":"Choi","year":"2023","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.biopha.2023.115292_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.pep.2022.106208","article-title":"Optimization of the expression of the main protease from SARS-CoV-2","volume":"203","author":"Rong","year":"2023","journal-title":"Protein Expr. Purif."},{"issue":"2","key":"10.1016\/j.biopha.2023.115292_bib65","first-page":"190","article-title":"Enhanced solubility and one-step purification of functional dimeric carboxypeptidase G2","volume":"86","author":"Khodakarami","year":"2021","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.biopha.2023.115292_bib66","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0141-0229(88)90007-5","article-title":"Purification of proteins by aqueous two-phase partition in novel acrylic co-polymer systems","volume":"10","author":"Hughes","year":"1988","journal-title":"Enzym. Microb. Technol."},{"key":"10.1016\/j.biopha.2023.115292_bib67","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/312709","article-title":"Preparative purification of recombinant proteins: current status and future trends","volume":"2013","author":"Saraswat","year":"2013","journal-title":"BioMed. Res. Int."},{"issue":"5","key":"10.1016\/j.biopha.2023.115292_bib68","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.3390\/cancers15051459","article-title":"A systematic review of high-dose methotrexate for adults with primary central nervous system lymphoma","volume":"15","author":"Villanueva","year":"2023","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.biopha.2023.115292_bib69","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10147-023-02307-z","article-title":"Nephrotoxicity associated with anticancer agents: perspective on onconephrology from nephrologists","volume":"28","author":"Matsubara","year":"2023","journal-title":"Int. J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2023.115292_bib70","first-page":"732","article-title":"Glucarpidase (voraxaze), a carboxypeptidase enzyme for methotrexate toxicity","volume":"38","author":"Rattu","year":"2013","journal-title":"P T."},{"key":"10.1016\/j.biopha.2023.115292_bib71","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/CEOR.S188786","article-title":"Length of stay, mortality, and readmissions among Medicare cancer patients treated with glucarpidase and conventional care: a retrospective study","volume":"11","author":"Demiralp","year":"2019","journal-title":"Clin. Outcomes Res."},{"issue":"5","key":"10.1016\/j.biopha.2023.115292_bib72","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.21873\/anticanres.16351","article-title":"Pharmacokinetics and pharmacodynamics of glucarpidase rescue treatment after high-dose methotrexate therapy based on modeling and simulation","volume":"43","author":"Kimura","year":"2023","journal-title":"Anticancer Res."},{"key":"10.1016\/j.biopha.2023.115292_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106416","article-title":"External evaluation and systematic review of population pharmacokinetic models for high-dose methotrexate in cancer patients","author":"Yang","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2023.115292_bib74","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/FTD.0000000000000085","article-title":"Using fluorescence polarization immunoassay for determination of erythrocyte methotrexate polyglutamates, a quick and easy test","volume":"36","author":"Den Boer","year":"2014","journal-title":"Ther. Drug Monit."},{"issue":"3","key":"10.1016\/j.biopha.2023.115292_bib75","article-title":"Monitoring methotrexate levels in a patient after glucarpidase administration: a case report","volume":"10","author":"Gulley","year":"2020","journal-title":"J. Hematol. Oncol. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2023.115292_bib76","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/FTD.0b013e31824b93a5","article-title":"Improved sensitivity for methotrexate analysis using enzyme multiplied immunoassay technique on the siemens Viva-E instrument","volume":"34","author":"Borgman","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.biopha.2023.115292_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114662","article-title":"Effects of different conformations of polylysine on the anti-tumor efficacy of methotrexate nanoparticles","volume":"162","author":"Yu","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2023.115292_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2022.100471","article-title":"CNS penetration of methotrexate and its metabolite 7-hydroxymethotrexate in mice bearing orthotopic Group 3 medulloblastoma tumors and model-based simulations for children","volume":"48","author":"Perkins","year":"2023","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.biopha.2023.115292_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2021.122247","article-title":"A review on analytical methods with special reference to electroanalytical methods for the determination of some anticancer drugs in pharmaceutical and biological samples","volume":"229","author":"Safaei","year":"2021","journal-title":"Talanta"},{"issue":"6","key":"10.1016\/j.biopha.2023.115292_bib80","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jsps.2023.04.007","article-title":"Evaluation of solid-lipid nanoparticles formulation of methotrexate for anti-psoriatic activity","volume":"31","author":"Maiti","year":"2023","journal-title":"Saudi Pharm. J."},{"issue":"3","key":"10.1016\/j.biopha.2023.115292_bib81","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/1097-0142(19950801)76:3<521::AID-CNCR2820760325>3.0.CO;2-M","article-title":"Carboxypeptidase\u2010G2 rescue in a patient with high dose methotrexate\u2010induced nephrotoxicity","volume":"76","author":"Widemann","year":"1995","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2023.115292_bib82","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/MPH.0000000000001058","article-title":"Delayed methotrexate clearance despite carboxypeptidase-G2 (glucarpidase) administration in 2 patients with toxic methotrexate levels","volume":"40","author":"Wyatt","year":"2018","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115292_bib83","first-page":"1","article-title":"Role of glucarpidase for intoxication of high dose methotrexate toxicity","volume":"6","author":"KHADELA","year":"2019","journal-title":"J. Pharm. Appl. Sci. | July-Dec."},{"key":"10.1016\/j.biopha.2023.115292_bib84","doi-asserted-by":"crossref","first-page":"1130548","DOI":"10.3389\/fphar.2023.1130548","article-title":"Case report: hepatotoxicity and nephrotoxicity induced by methotrexate in a paediatric patient, what is the role of precision medicine in 2023","volume":"14","author":"El Masri","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115292_bib85","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/cpt.1957","article-title":"MTXPK.org: a clinical decision support tool evaluating high-dose methotrexate pharmacokinetics to inform post-infusion care and use of glucarpidase","volume":"108","author":"Taylor","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.biopha.2023.115292_bib86","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30506","article-title":"A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high-dose methotrexate therapy in open-label trials","volume":"70","author":"Janeway","year":"2023","journal-title":"Pediatr. Blood Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2023.115292_bib87","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annemergmed.2018.06.011","article-title":"Working through the paradox of methotrexate toxicity","volume":"72","author":"Vohra","year":"2018","journal-title":"Ann. Emerg. Med."},{"issue":"7","key":"10.1016\/j.biopha.2023.115292_bib88","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26395","article-title":"Delayed elimination of high\u2010dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia","volume":"64","author":"Svahn","year":"2017","journal-title":"Pediatr. blood Cancer"},{"issue":"25","key":"10.1016\/j.biopha.2023.115292_bib89","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2009.25.4540","article-title":"Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome","volume":"28","author":"Widemann","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2023.115292_bib90","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00280-004-0910-2","article-title":"Interactions of carboxypeptidase G2 with 6S-leucovorin and 6R-leucovorin in vitro: implications for the application in case of methotrexate intoxications","volume":"55","author":"Hempel","year":"2005","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115292_bib91","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2147\/CEOR.S397154","article-title":"Glucarpidase for treating adults with delayed methotrexate elimination due to impaired renal function: an economic simulation analysis","volume":"15","author":"Kala","year":"2023","journal-title":"Clin. Outcomes Res."},{"key":"10.1016\/j.biopha.2023.115292_bib92","doi-asserted-by":"crossref","unstructured":"Y. Garcilazo C. Soussain E. Tabouret G. Ahle A. Schimitt A. Waultier M. Blonski A. Liou-Schischmanoff K. Hoang-Xuan C. Houillier P14. 118 Carboxypeptidase G2 (CPG2) rescue after high dose methotrexate (hdMTX) chemotherapy for Primary CNS Lymphoma (PCNSL) A Fr. LOC Netw. Study Neuro-Oncol. 21 Supplement_3 2019.iii96-iii96.","DOI":"10.1093\/neuonc\/noz126.353"},{"key":"10.1016\/j.biopha.2023.115292_bib93","doi-asserted-by":"crossref","unstructured":"A. Egan, C. Daniels, A denuding drug: A case of methotrexate-induced toxic epidermal necrolysis, C42. CRITICAL CARE CASE REPORTS: TOXICOLOGY AND POISONINGS 2, American Thoracic Society2019, pp. A4853-A4853.","DOI":"10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A4853"},{"issue":"5\u20136","key":"10.1016\/j.biopha.2023.115292_bib94","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1080\/08880018.2018.1524536","article-title":"Treatment of two cases on the same day of intrathecal methotrexate overdose using cerebrospinal fluid exchange and intrathecal instillation of carboxypeptidase-G2","volume":"35","author":"Wormdal","year":"2018","journal-title":"Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2023.115292_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.635152","article-title":"Charcoal hemoperfusion for methotrexate toxicity: a safe and effective life-rescue alternative when glucarpidase is not available","volume":"9","author":"Rosales","year":"2021","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.biopha.2023.115292_bib96","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.82401","article-title":"SIMMER employs similarity algorithms to accurately identify human gut microbiome species and enzymes capable of known chemical transformations","volume":"12","author":"Bustion","year":"2023","journal-title":"Elife"},{"issue":"6","key":"10.1016\/j.biopha.2023.115292_bib97","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1016\/j.clml.2021.01.006","article-title":"Fixed-dose glucarpidase for toxic methotrexate levels and acute kidney injury in adult lymphoma patients: case series","volume":"21","author":"Truong","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"8","key":"10.1016\/j.biopha.2023.115292_bib98","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1200\/JCO.1992.10.8.1359","article-title":"Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys","volume":"10","author":"Adamson","year":"1992","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2023.115292_bib99","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1310\/hpj4706-463","article-title":"Glucarpidase","volume":"47","author":"Cada","year":"2012","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.biopha.2023.115292_bib100","doi-asserted-by":"crossref","unstructured":"C.A. Thompson CMS to compensate hospitals for inpatient use of fidaxomicin, glucarpidase Oxf. Univ. Press 2012.","DOI":"10.2146\/news120070"},{"issue":"9","key":"10.1016\/j.biopha.2023.115292_bib101","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1002\/pbc.25577","article-title":"Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction","volume":"62","author":"Widemann","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2023.115292_bib102","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00280-021-04361-8","article-title":"Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury","volume":"89","author":"Heuschkel","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115292_bib103","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/pbc.22811","article-title":"Low-dose carboxypeptidase-G2 for methotrexate toxicity in a child","volume":"55","author":"Qudsi","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2023.115292_bib104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-09164-x","article-title":"Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study","volume":"22","author":"Schaff","year":"2022","journal-title":"BMC Cancer"},{"issue":"20","key":"10.1016\/j.biopha.2023.115292_bib105","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/jnci\/djh270","article-title":"Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2","volume":"96","author":"Widemann","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.biopha.2023.115292_bib106","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1177\/1078155220946464","article-title":"A second administration of glucarpidase in a different cycle of high-dose methotrexate: is it safe and effective in adults","volume":"27","author":"Domingo-Gonz\u00e1lez","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"5","key":"10.1016\/j.biopha.2023.115292_bib107","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/phar.1360","article-title":"Efficacy of Glucarpidase (Carboxypeptidase G2) in patients with acute kidney injury after high-dose methotrexate therapy","volume":"34","author":"Widemann","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"8","key":"10.1016\/j.biopha.2023.115292_bib108","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29036","article-title":"Novel risk factors for glucarpidase use in pediatric acute lymphoblastic leukemia: hispanic ethnicity, age, and the ABCC4 gene","volume":"68","author":"Zobeck","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2023.115292_bib109","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/phar.2779","article-title":"Novel and replicated clinical and genetic risk factors for toxicity from high-dose methotrexate in pediatric acute lymphoblastic leukemia","volume":"43","author":"Zobeck","year":"2023","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"issue":"8","key":"10.1016\/j.biopha.2023.115292_bib110","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/cncr.34646","article-title":"Ethnic-specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high-dose methotrexate","volume":"129","author":"Harris","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2023.115292_bib111","doi-asserted-by":"crossref","DOI":"10.1021\/acs.chemrev.2c00915","article-title":"The dawn of a new era: targeting the \u201cundruggables\u201d with antibody-based therapeutics","author":"Qian","year":"2023","journal-title":"Chem. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2023.115292_bib112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14712598.2017.1247802","article-title":"Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination","volume":"17","author":"Sharma","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"issue":"12","key":"10.1016\/j.biopha.2023.115292_bib113","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.tips.2021.09.009","article-title":"Engineered antibody fusion proteins for targeted disease therapy","volume":"42","author":"Silver","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2023.115292_bib114","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/14737140.2019.1615890","article-title":"Prodrugs for targeted cancer therapy","volume":"19","author":"Souza","year":"2019","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.biopha.2023.115292_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.nano.2021.102424","article-title":"An antibody-based enzymatic therapy for cancer treatment: the selective localization of D-amino acid oxidase to EDA fibronectin","volume":"36","author":"Rosini","year":"2021","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"issue":"1","key":"10.1016\/j.biopha.2023.115292_bib116","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1007\/PL00014055","article-title":"Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer","volume":"46","author":"Chester","year":"2000","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115292_bib117","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/sj.cgt.7701100","article-title":"Tumor targeting carboxylesterase fused with anti-CEA scFv improve the anticancer effect with a less toxic dose of irinotecan","volume":"15","author":"Uchino","year":"2008","journal-title":"Cancer gene Ther."},{"key":"10.1016\/j.biopha.2023.115292_bib118","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/980250","article-title":"scFv antibody: principles and clinical application","volume":"2012","author":"Ahmad","year":"2012","journal-title":"Clin. Dev. Immunol."},{"issue":"10","key":"10.1016\/j.biopha.2023.115292_bib119","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1021\/nn402644g","article-title":"Effect of folate-targeted nanoparticle size on their rates of penetration into solid tumors","volume":"7","author":"Vlashi","year":"2013","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.biopha.2023.115292_bib120","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jconrel.2012.02.020","article-title":"Novel cathepsin B-sensitive paclitaxel conjugate: higher water solubility, better efficacy and lower toxicity","volume":"160","author":"Liang","year":"2012","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.biopha.2023.115292_bib121","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/1380-2933(96)00033-4","article-title":"In vitro and in vivo characterisation of a recombinant carboxypeptidase G2::anti-CEA scFv fusion protein","volume":"2","author":"Michael","year":"1996","journal-title":"Immunotechnology"},{"issue":"11","key":"10.1016\/j.biopha.2023.115292_bib122","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/0277-5379(91)90010-B","article-title":"Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds","volume":"27","author":"Springer","year":"1991","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2023.115292_bib123","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0022-1759(93)90257-8","article-title":"Optimisation of small-scale coupling of A5B7 monoclonal antibody to carboxypeptidase G2","volume":"158","author":"Melton","year":"1993","journal-title":"J. Immunol. Methods"},{"issue":"3","key":"10.1016\/j.biopha.2023.115292_bib124","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/bjc.1986.62","article-title":"The potential of carboxypeptidase G2-antibody conjugates as anti-tumour agents. I. preparation of antihuman chorionic gonadotrophin-carboxypeptidase G2 and cytotoxicity of the conjugate against JAR choriocarcinoma cells in vitro","volume":"53","author":"Searle","year":"1986","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2023.115292_bib125","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/glycob\/cwl053","article-title":"Clearance mechanism of a mannosylated antibody - enzyme fusion protein used in experimental cancer therapy","volume":"17","author":"Kogelberg","year":"2007","journal-title":"Glycobiology"},{"issue":"4","key":"10.1016\/j.biopha.2023.115292_bib126","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/(SICI)1097-0215(20000215)85:4<571::AID-IJC20>3.0.CO;2-1","article-title":"Catalytic activity of an in vivo tumor targeted anti\u2010CEA scFv:: carboxypeptidase G2 fusion protein","volume":"85","author":"Bhatia","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2023.115292_bib127","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ejmech.2018.04.001","article-title":"Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives","volume":"151","author":"Singh","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2023.115292_bib128","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1021\/jm00164a034","article-title":"Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2","volume":"33","author":"Springer","year":"1990","journal-title":"J. Med Chem."},{"issue":"15","key":"10.1016\/j.biopha.2023.115292_bib129","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1021\/jm00041a015","article-title":"Novel prodrugs of alkylating agents derived from 2-Fluoro- and 3-Fluorobenzoic acids for antibody-directed enzyme prodrug therapy","volume":"37","author":"Springer","year":"1994","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.biopha.2023.115292_bib130","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/bjc.1995.469","article-title":"Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs","volume":"72","author":"Blakey","year":"1995","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2023.115292_bib131","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.bmcl.2005.10.017","article-title":"Synthesis and biological evaluation of novel pyrrolo 2,1-c 1,4 benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy","volume":"16","author":"Masterson","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.biopha.2023.115292_bib132","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/10611860600834573","article-title":"Diethylstilbestrol glutamate as a potential substrate for ADEPT","volume":"14","author":"Pedone","year":"2006","journal-title":"J. Drug Target."},{"issue":"1\u20133","key":"10.1016\/j.biopha.2023.115292_bib133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03033863","article-title":"Antitumor effects of an antibody-carboxypeptidase g2 conjugate in combination with a benzoic acid mustard prodrug","volume":"22","author":"Blakey","year":"1993","journal-title":"Cell Biophys."},{"issue":"3","key":"10.1016\/j.biopha.2023.115292_bib134","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3892\/ijo.9.3.567","article-title":"Antibody-directed enzyme prodrug therapy (ADEPT)","volume":"9","author":"Retta","year":"1996","journal-title":"Int. J. Oncol."},{"issue":"19","key":"10.1016\/j.biopha.2023.115292_bib135","first-page":"5171","article-title":"Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185","volume":"54","author":"Eccles","year":"1994","journal-title":"Cancer Res."},{"issue":"26","key":"10.1016\/j.biopha.2023.115292_bib136","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1021\/jm00026a013","article-title":"Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for Antibody-Directed Enzyme Prodrug Therapy (ADEPT)","volume":"38","author":"Springer","year":"1995","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.biopha.2023.115292_bib137","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1054\/bjoc.2001.1843","article-title":"Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material","volume":"84","author":"Webley","year":"2001","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2023.115292_bib138","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1054\/bjoc.2001.1947","article-title":"Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue","volume":"85","author":"Monks","year":"2001","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.biopha.2023.115292_bib139","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0959-8049(02)00111-9","article-title":"DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767","volume":"38","author":"Monks","year":"2002","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2023.115292_bib140","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26030625","article-title":"Coupling of a novel timp3 peptide to carboxypeptidase g2 for pro-drug activation at the tumour site","volume":"26","author":"Aldughaim","year":"2021","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.biopha.2023.115292_bib141","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1021\/acs.molpharmaceut.0c00008","article-title":"Ultrasound enhances ZD2767P-Carboxypeptidase G2 against chemoresistant ovarian cancer cells by altering the intracellular pharmacokinetics of ZD2767D","volume":"17","author":"Liu","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2023.115292_bib142","first-page":"2164","article-title":"Development of ZD2767P\u2013carboxypeptidase G2\u2013ultrasound therapy against cisplatin-resistant cancer","volume":"13","author":"Yu","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2023.115292_bib143","doi-asserted-by":"crossref","first-page":"9191233","DOI":"10.1155\/2022\/9191233","article-title":"Ultrasonically Enhanced ZD2767P\u2013Carboxypeptidase G2 deactivates cisplatin-resistant human lung cancer cells","author":"Liu","year":"2022","journal-title":"Oxid. Med. Cell. Longev. 2022"},{"issue":"4","key":"10.1016\/j.biopha.2023.115292_bib144","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002800050659","article-title":"Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft","volume":"40","author":"Stribbling","year":"1997","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2023.115292_bib145","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/bjc.1988.293","article-title":"A cytotoxic agent can be generated selectively at cancer sites","volume":"58","author":"Bagshawe","year":"1988","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2023.115292_bib146","first-page":"467","article-title":"Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT)","volume":"6","author":"Springer","year":"1991","journal-title":"Anti-Cancer Drug Des."},{"issue":"2","key":"10.1016\/j.biopha.2023.115292_bib147","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF00689806","article-title":"Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs)","volume":"12","author":"Denny","year":"1993","journal-title":"Cancer Metastas. Rev."},{"issue":"14","key":"10.1016\/j.biopha.2023.115292_bib148","first-page":"3287","article-title":"ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts","volume":"56","author":"Blakey","year":"1996","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2023.115292_bib149","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/bjc.1990.92","article-title":"The potential of carboxypeptidase g2: antibody conjugates as anti-tumour agents. ii. in vivo localising and clearance properties in a choriocarcinoma model","volume":"61","author":"Melton","year":"1990","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2023.115292_bib150","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/bjc.1990.149","article-title":"Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model","volume":"61","author":"Sharma","year":"1990","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2023.115292_bib151","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/bjc.1995.515","article-title":"Plasma clearance of an antibody-enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo","volume":"72","author":"Rogers","year":"1995","journal-title":"Br. J. Cancer"},{"issue":"1\u20133","key":"10.1016\/j.biopha.2023.115292_bib152","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF02789232","article-title":"Antibody-directed enzyme prodrug therapy (ADEPT) - a three-phase study in ovarian tumor xenografts","volume":"24\u201325","author":"Sharma","year":"1994","journal-title":"Cell Biophys."},{"issue":"3 Suppl","key":"10.1016\/j.biopha.2023.115292_bib153","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/1097-0142(19940201)73:3+<1114::AID-CNCR2820731352>3.0.CO;2-L","article-title":"Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy","volume":"73","author":"Sharma","year":"1994","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2023.115292_bib154","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1021\/jm990004i","article-title":"Novel inhibitors of carboxypeptidase G2 (CPG2): potential use in antibody-directed enzyme prodrug therapy","volume":"42","author":"Khan","year":"1999","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2023.115292_bib155","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0968-0896(00)00254-6","article-title":"Stereoselective inhibition of glutamate carboxypeptidase by chiral phosphonothioic acids","volume":"9","author":"Lu","year":"2001","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.biopha.2023.115292_bib156","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bioelechem.2014.07.001","article-title":"Nanosecond electric pulses deprive zinc ions of carboxypeptidase G2","volume":"101","author":"Yu","year":"2015","journal-title":"Bioelectrochemistry"},{"issue":"8","key":"10.1016\/j.biopha.2023.115292_bib157","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S0959-8049(05)80311-9","article-title":"Tumour necrosis factor increases tumour uptake of co-administered antibody-carboxypeptidase G2 conjugate","volume":"29a","author":"Melton","year":"1993","journal-title":"Eur. J. Cancer"},{"issue":"16","key":"10.1016\/j.biopha.2023.115292_bib158","first-page":"3998","article-title":"Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent","volume":"59","author":"Pedley","year":"1999","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2023.115292_bib159","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/protein\/gzx005","article-title":"Engineering carboxypeptidase G2 circular permutations for the design of an autoinhibited enzyme","volume":"30","author":"Yachnin","year":"2017","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.biopha.2023.115292_bib160","first-page":"1","article-title":"Optimizing the safety of antibody\u2013drug conjugates for patients with solid tumours","author":"Tarantino","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115292_bib161","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1158\/1078-0432.814.11.2","article-title":"Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy","volume":"11","author":"Sharma","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"1\u20133","key":"10.1016\/j.biopha.2023.115292_bib162","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF02789482","article-title":"Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial","volume":"21","author":"Sharma","year":"1992","journal-title":"Cell Biophys."},{"key":"10.1016\/j.biopha.2023.115292_bib163","first-page":"3156","article-title":"Cyclosporine delays host immune response to antibody enzyme conjugate in ADEPT","author":"Bagshawe","year":"1996","journal-title":"Transplant. Proc."},{"issue":"4","key":"10.1016\/j.biopha.2023.115292_bib164","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196254","article-title":"Isolation and molecular characterization of novel glucarpidases: enzymes to improve the antibody directed enzyme pro-drug therapy for cancer treatment","volume":"13","author":"Rashidi","year":"2018","journal-title":"Plos One"},{"issue":"3","key":"10.1016\/j.biopha.2023.115292_bib165","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s002800050646","article-title":"Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial","volume":"40","author":"Martin","year":"1997","journal-title":"Cancer Chemother. Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2023.115292_bib166","first-page":"765","article-title":"Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma, clinical cancer research: an official journal of the American","volume":"6","author":"Napier","year":"2000","journal-title":"Assoc. Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2023.115292_bib167","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/1615-9861(200203)2:3<271::AID-PROT271>3.0.CO;2-W","article-title":"A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics","volume":"2","author":"Spencer","year":"2002","journal-title":"Proteomics"},{"issue":"12","key":"10.1016\/j.biopha.2023.115292_bib168","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/sj.bjc.6601888","article-title":"Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT)","volume":"90","author":"Mayer","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"21","key":"10.1016\/j.biopha.2023.115292_bib169","first-page":"6509","volume":"12","author":"Mayer","year":"2006","journal-title":"Assoc. Cancer Res."},{"issue":"6","key":"10.1016\/j.biopha.2023.115292_bib170","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/sj.bjc.6600517","article-title":"A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours","volume":"87","author":"Francis","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2023.115292_bib171","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ejmech.2017.08.010","article-title":"Prodrug strategy for cancer cell-specific targeting: a recent overview","volume":"139","author":"Zhang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.biopha.2023.115292_bib172","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1517\/17425255.2014.967679","article-title":"Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns","volume":"10","author":"Zhang","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.biopha.2023.115292_bib173","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/9783527827855.ch6","article-title":"Gene\u2010Directed Enzyme\u2013Prodrug Therapy (GDEPT) as a suicide gene therapy modality for cancer treatment","author":"Kharkar","year":"2022","journal-title":"Target. Drug Deliv."},{"issue":"19","key":"10.1016\/j.biopha.2023.115292_bib174","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.3390\/molecules26195976","article-title":"Dendrimers as non-viral vectors in gene-directed enzyme prodrug therapy","volume":"26","author":"Chis","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2023.115292_bib175","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e10660","article-title":"Microbial cytosine deaminase is a programmable anticancer prodrug mediating enzyme: antibody, and gene directed enzyme prodrug therapy","author":"El-Sayed","year":"2022","journal-title":"Heliyon"},{"issue":"26","key":"10.1016\/j.biopha.2023.115292_bib176","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1021\/jm980425k","article-title":"Self-immolative nitrogen mustard prodrugs for suicide gene therapy dan niculescu-duvaz, ion niculescu-duvaz, frank friedlos, janet martin, robert spooner","volume":"41","author":"Davies","year":"1998","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.biopha.2023.115292_bib177","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1021\/jm980696v","article-title":"Self-immolative anthracycline prodrugs for suicide gene therapy","volume":"42","author":"Niculescu-Duvaz","year":"1999","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2023.115292_bib178","first-page":"1724","article-title":"Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models","volume":"62","author":"Friedlos","year":"2002","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.biopha.2023.115292_bib179","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1021\/jm020462i","article-title":"Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT","volume":"46","author":"Niculescu-Duvaz","year":"2003","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.biopha.2023.115292_bib180","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1021\/jm030966w","article-title":"Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems","volume":"47","author":"Niculescu-Duvaz","year":"2004","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.biopha.2023.115292_bib181","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1021\/jm0502182","article-title":"Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy","volume":"48","author":"Davies","year":"2005","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.biopha.2023.115292_bib182","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/nbt1297-1373","article-title":"A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy","volume":"15","author":"Marais","year":"1997","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2023.115292_bib183","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1208\/s12248-014-9675-7","article-title":"Gene-directed enzyme prodrug therapy","volume":"17","author":"Zhang","year":"2015","journal-title":"AAPS J."},{"issue":"11","key":"10.1016\/j.biopha.2023.115292_bib184","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/sj.cgt.7700514","article-title":"Adenovirus vector-mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane","volume":"9","author":"Cowen","year":"2002","journal-title":"Cancer Gene Ther."},{"issue":"12","key":"10.1016\/j.biopha.2023.115292_bib185","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/0008-5472.CAN-05-0393","article-title":"Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2","volume":"65","author":"Schepelmann","year":"2005","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2023.115292_bib186","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10","key":"10.1016\/j.biopha.2023.115292_bib187","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1158\/0008-5472.CAN-07-0297","article-title":"Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2","volume":"67","author":"Schepelmann","year":"2007","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.biopha.2023.115292_bib188","doi-asserted-by":"crossref","first-page":"2205641","DOI":"10.1002\/advs.202205641","article-title":"Bacterial-mediated tumor therapy: old treatment in a new context","volume":"10","author":"Liu","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.biopha.2023.115292_bib189","doi-asserted-by":"crossref","first-page":"1048360","DOI":"10.3389\/fcell.2022.1048360","article-title":"Tumor resident microbiota and response to therapies: an insight on tissue bacterial microbiota","volume":"10","author":"Pirini","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"issue":"13","key":"10.1016\/j.biopha.2023.115292_bib190","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1158\/1078-0432.CCR-07-4800","article-title":"Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy","volume":"14","author":"Friedlos","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"20","key":"10.1016\/j.biopha.2023.115292_bib191","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.3390\/molecules24203744","article-title":"Biodegradable polymers for gene delivery","volume":"24","author":"Thomas","year":"2019","journal-title":"Molecules"},{"issue":"6382","key":"10.1016\/j.biopha.2023.115292_bib192","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.biopha.2023.115292_bib193","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coi.2016.06.004","article-title":"Chimeric antigen receptors: driving immunology towards synthetic biology","volume":"41","author":"Sadelain","year":"2016","journal-title":"Curr. Opin. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115292_bib194","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41589-021-00932-1","article-title":"Engineering CAR-T cells to activate small-molecule drugs in situ","volume":"18","author":"Gardner","year":"2022","journal-title":"Nat. Chem. Biol."},{"issue":"8","key":"10.1016\/j.biopha.2023.115292_bib195","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.3390\/cancers12082175","article-title":"Targeted cellular micropharmacies: cells engineered for localized drug delivery","volume":"12","author":"Gardner","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2023.115292_bib196","doi-asserted-by":"crossref","DOI":"10.1016\/j.tips.2022.04.001","article-title":"SEAKER cells coordinate cellular immunotherapy with localized chemotherapy","author":"Lane","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2023.115292_bib197","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41589-021-00933-0","article-title":"CAR-T cells SEAK help from enzymes","volume":"18","author":"Vincent","year":"2022","journal-title":"Nat. Chem. Biol."},{"issue":"18","key":"10.1016\/j.biopha.2023.115292_bib198","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","article-title":"Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts","volume":"13","author":"Brentjens","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2023.115292_bib199","first-page":"OF1","article-title":"Host interactions with engineered T-cell micropharmacies","author":"Bourne","year":"2023","journal-title":"Cancer Immunol. Res."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223010831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223010831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T06:54:39Z","timestamp":1782370479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223010831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":199,"alternative-id":["S0753332223010831"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115292","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucarpidase (carboxypeptidase G2): Biotechnological production, clinical application as a methotrexate antidote, and placement in targeted cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115292","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115292"}}